Work

A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.tps2606

Authors: Howard A. Burris, Minal A. Barve, Erika Paige Hamilton, Aditya Bardia, Hatem Hussein Soliman, Donna Jarlenski, Rebecca Mosher, Donald Alan Bergstrom

Institutions: Sarah Cannon, Texas Oncology, Tennessee Oncology, Massachusetts General Hospital, Moffitt Cancer Center, Mersana Therapeutics (United States)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890151020

Cites:

Cited by: 5

Related to: 10